Ono Entered into an Agreement with Domain and Université de Montréal to Discover Small Molecules Targeting G-Protein Coupled Receptors
Shots:
- Domain and UdM to receive an upfront & is also eligible to receive research funding for research programs, success-based milestones on the R&D progress along with royalties on future sales
- Ono to get an exclusive right globally to develop and commercialize the product that emerges from the collaboration
- The collaboration will use Domain’s and UdM’s bioSens-All technology GPCR drug discovery platform (in-licensed by Domain from UdM) & expertise in GPCR medicinal chemistry & pharmacology to optimize small molecules against GPCR selected for a drug development program to treat metabolic disease. The technology helps to detect the proximal signaling pathways of GPCR
Ref: Ono | Image: Ono
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
